What indirectly links brain disease to COVID-19?

Armin Bayati’s undergraduate years cemented his dual fascination with biology and the brain. 

Bayati earned a bachelor’s degree in biology and psychology with distinction at the University of Victoria in British Columbia, where he worked at a medical sciences lab and started doing electron microscopy, a technique used to capture high-resolution images of a variety of specimens, such as cells and biopsy samples. He became intrigued by cellular functions and structures.

Armin Bayati

At the same time, Bayati worked at Saint Joseph’s Hospital as an activity coordinator for patients with a variety of disorders, the most common symptom being dementia. Witnessing the cognitive decline of patients with nervous system disorders got him interested in neuroscience. “A lot of what affects the elderly’s independence is neurological disorders, such as dementia, Alzheimer’s, or movement disorders like Parkinson’s and Huntington’s disease,” he said. “So that’s where my interest in the neurological aspects of things comes in.” 

These experiences led Bayati to study the biological mechanisms behind neurodegenerative disorders at a cellular level. Now a Ph.D. candidate at the Montréal Neurological Institute and Hospital at McGill University, he works in Peter McPherson’s lab, where his research focuses on alpha-synuclein, a neuronal protein linked to Parkinson’s disease and other disorders. He investigates how the pathological form of alpha-synuclein is brought into cells and what type of endocytosis occurs.

Bayati recently has used his expertise in endocytosis to study the virus that causes COVID-19. “We were looking at how pathological alpha-synuclein enters the cell,” he said. “The problem with COVID was the same thing. How does the virus enter the cell? It would be the same kind of experiments as we’d do for looking at the internalization of alpha-synuclein, but then I applied it to finding how the spike protein enters the cell.”